Merck Says Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) Of Keytruda Combined With Chemo Met Its Secondary Endpoint Of Overall Survival For Platinum-resistant Recurrent Ovarian Cancer In All Comers

-1.16%

Merck & Co., Inc.

MRK

99.72

-1.16%

KEYNOTE-B96 is the first trial of an immune checkpoint inhibitor-based treatment regimen in platinum-resistant recurrent ovarian cancer to show a statistically significant improvement in OS versus placebo plus chemotherapy with or without bevacizumab for patients whose tumors express PD-L1 and in all comers
These data add to previous results for the primary endpoint of progression-free survival and key secondary endpoint of OS

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.